239 related articles for article (PubMed ID: 33051308)
1.
Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
3. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
Adachi JI; Shirahata M; Suzuki T; Mishima K; Uchida E; Sasaki A; Nishikawa R
Brain Tumor Pathol; 2021 Jul; 38(3):201-209. PubMed ID: 34128111
[TBL] [Abstract][Full Text] [Related]
4. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
5. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
[TBL] [Abstract][Full Text] [Related]
6. Human TERT promoter mutations as a prognostic biomarker in glioma.
Powter B; Jeffreys SA; Sareen H; Cooper A; Brungs D; Po J; Roberts T; Koh ES; Scott KF; Sajinovic M; Vessey JY; de Souza P; Becker TM
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1007-1017. PubMed ID: 33547950
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
8. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
[TBL] [Abstract][Full Text] [Related]
9. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
10. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
[TBL] [Abstract][Full Text] [Related]
11. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.
Corless BC; Chang GA; Cooper S; Syeda MM; Shao Y; Osman I; Karlin-Neumann G; Polsky D
J Mol Diagn; 2019 Mar; 21(2):274-285. PubMed ID: 30827467
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
15. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
[TBL] [Abstract][Full Text] [Related]
18. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
[TBL] [Abstract][Full Text] [Related]
19. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
[TBL] [Abstract][Full Text] [Related]
20. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
